Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9936387 | 0.83 | L3MBTL1 (0.31) | — | |
| SCHEMBL8701295 | 0.78 | L3MBTL1 (0.33) | ALDH1A1 | |
| SCHEMBL28023530 | 0.77 | L3MBTL1 (0.32) | — | |
| SCHEMBL5112834 | 0.75 | L3MBTL1 (0.31) | — | |
| SCHEMBL27858121 | 0.75 | L3MBTL1 (0.34) | ALDH1A1POLBHTTSMN1; SMN2 | |
| SCHEMBL18429007 | 0.75 | CHRM2 (0.35) | ALDH1A1HTTSMN1; SMN2 | |
| SCHEMBL9547534 | 0.73 | L3MBTL1 (0.36) | ALDH1A1SMN1; SMN2LMNA | |
| SCHEMBL9013395 | 0.73 | ALDH1A1 (0.37) | ALDH1A1SMN1; SMN2RAB9ALMNA | |
| SCHEMBL3541908 | 0.73 | MEN1 (0.32) | — | |
| SCHEMBL27651002 | 0.71 | MEN1 (0.32) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8183234-B2 | Tricyclic guanidine derivatives as sodium-proton exchange inhibitors | PIRAMAL LIFE SCIENCES LIMITED (IN) | 2012-05-22 | — | — | US | disclosed |
| US-20100267690-A1 | TRICYCLIC GUANIDINE DERIVATIVES AS SODIUM-PROTON EXCHANGE INHIBITORS | PIRAMAL LIFE SCIENCES LIMITED (IN) | 2010-10-21 | — | — | US | disclosed |
| EP-1812420-A1 | TRICYCLIC GUANIDINE DERIVATIVES AS SODIUM-PROTON EXCHANGE INHIBITORS | Nicholas Piramal India Limited (IN) | 2007-08-01 | — | — | EP | disclosed |
| WO-2006051476-A1 | TRICYCLIC GUANIDINE DERIVATIVES AS SODIUM-PROTON EXCHANGE INHIBITORS | NICHOLAS PIRAMAL INDIA LIMITED (IN) | 2006-05-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100267690-A1 | TRICYCLIC GUANIDINE DERIVATIVES AS SODIUM-PROTON EXCHANGE INHIBITORS | ATP2A1, ATP2A3, KCNN4 | ALDH1A1 1222/4885POLB 862/4885HTT 3522/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.